

SIERRA LEONE

Support for Rotavirus Vaccine

This Decision Letter sets out the Programme Terms of a Programme

1. Country:	Sierra Leone						
2. Vaccine grant number:	12-SLE-08a-Y, 1215-SLE-13b-X, 16-SLE-13b-X, 17-SLE-13b-X, 1821-SLE-13b-X						
3. Date of Decision Letter:	30-Sep-2019						
4. Date of the Partnership Framework Agreement:	3/10/2013						
5. Programme title:	New Vaccine Support (NVS), Rotavirus, Routine						
6. Vaccine type:	Rotavirus						
7. Requested product presentation and formulation of vaccine:	RV1, 1 dose/plastic tube, liq						
8. Programme Duration:¹	2014-2021						
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2014-2019	2020	2021	2022	2023	2024	Total ²
Programme Budget (US\$)	5,889,161	82,000	958,000	-	-	-	6,929,161
10. Vaccine introduction grant							
	Approval						
	Year	Grant Number					Amount (US\$)
	2012	12-SLE-08a-Y					193,500
	Disbursement						
	Disbursement date						Amount (US\$)
	06 May, 2014						193,500
11. Product switch grant	Not applicable						
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement, if applicable)						
Type of supplies to be purchased with Gavi funds	2015-2019	2020					2021
Number of vaccine doses		33,900					-

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

Annual Amounts (US\$)	5,889,161	82,000	-																																										
13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.																																												
14. Self-procurement:	Not applicable																																												
15. Co-financing obligations:	<p>According to the co-financing policy, the Country falls within the group: Initial self-financing</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2020</th> <th>2021</th> <th>2022</th> <th>2023</th> <th>2024</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>9,000</td> <td>39,000</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Number of AD syringes</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Number of re-constitution syringes</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Number of safety boxes</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>18,126</td> <td>87,205</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>19,000</td> <td>89,500</td> <td>-</td> <td>-</td> <td>-</td> </tr> </tbody> </table>			Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024	Number of vaccine doses	9,000	39,000	-	-	-	Number of AD syringes	-	-	-	-	-	Number of re-constitution syringes	-	-	-	-	-	Number of safety boxes	-	-	-	-	-	Value of vaccine doses (US\$)	18,126	87,205	-	-	-	Total co-financing payments (US\$) (including freight)	19,000	89,500	-	-	-
Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024																																								
Number of vaccine doses	9,000	39,000	-	-	-																																								
Number of AD syringes	-	-	-	-	-																																								
Number of re-constitution syringes	-	-	-	-	-																																								
Number of safety boxes	-	-	-	-	-																																								
Value of vaccine doses (US\$)	18,126	87,205	-	-	-																																								
Total co-financing payments (US\$) (including freight)	19,000	89,500	-	-	-																																								
16. Operational support for campaigns:	Not applicable																																												
17. Additional Reporting Requirements:	<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> Vaccine stock levels including buffer stock Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received Countries shall report the actual switch date in the first renewal request following the actual implementation </td> <td> 31 March 2020 15 May 2020 </td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>				Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> Vaccine stock levels including buffer stock Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received Countries shall report the actual switch date in the first renewal request following the actual implementation 	31 March 2020 15 May 2020	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat																																				
	Due dates																																												
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> Vaccine stock levels including buffer stock Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received Countries shall report the actual switch date in the first renewal request following the actual implementation 	31 March 2020 15 May 2020																																												
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat																																												

18. Financial clarifications:	Not applicable
--------------------------------------	----------------

19. Other conditions:

Not applicable

Signed by,
On behalf of Gavi



Thabani Maphosa,
Managing Director, Country Programmes
30-Sep-2019